Latest News – Page 12 – Safe Biologics

ASBM Whitepaper Offers Critical Review of Canadian Substitution Policies

August 22, 2021

On August 22nd, the Journal of the Generics and Biosimilars Journal (GaBI Journal) published a new whitepaper by ASBM Executive Director Michael Reilly and Advisory Board Chair Philip Schneider. The paper is entitled “A Critical Review of Substitution Policy for Biosimilars in Canada” and highlights the stark contrast between the forced-substitution policies recently enacted by some Canadian provinces and the pro-competition […]

ASBM Whitepaper Offers Critical Review of Canadian Substitution Policies

August 22, 2021

On August 22nd, the Journal of the Generics and Biosimilars Journal (GaBI Journal) published a new whitepaper by ASBM Executive Director Michael Reilly and Advisory Board Chair Philip Schneider. The paper is entitled “A Critical Review of Substitution Policy for Biosimilars in Canada” and highlights the stark contrast between the forced-substitution policies recently enacted by some Canadian provinces and the pro-competition […]

ASBM Letter to Congress Urges Level Playing Field for All Biologics

July 31, 2021

On July 28th, ASBM sent a letter to Congressional leaders expressing our opposition to H.R.2815, the BIOSIM Act, a bill “to amend title XVIII of the Social Security Act to provide for a temporary payment increase under the Medicare program for certain biosimilar biological products to encourage the development and use of such products.” The bill proposes […]

ASBM Letter to Congress Urges Level Playing Field for All Biologics

July 31, 2021

On July 28th, ASBM sent a letter to Congressional leaders expressing our opposition to H.R.2815, the BIOSIM Act, a bill “to amend title XVIII of the Social Security Act to provide for a temporary payment increase under the Medicare program for certain biosimilar biological products to encourage the development and use of such products.” The bill proposes […]

FDA Approves First Interchangable Biosimilar Insulin

July 28, 2021

On July 28th, the U.S. Food and Drug Administration (FDA) announced the long-awaited approved of the first interchangeable biosimilar, Mylan’s SemgleeⓇ. Under the Biologic Price Competition and Innovation Act (BPCIA) of 2009, which governs U.S. biosimilar development, an interchangeable biosimilar may be substituted in place of its reference product (in this case, Sanofi’s insulin glargine LantusⓇ) at the pharmacy without the […]

FDA Approves First Interchangable Biosimilar Insulin

July 28, 2021

On July 28th, the U.S. Food and Drug Administration (FDA) announced the long-awaited approved of the first interchangeable biosimilar, Mylan’s SemgleeⓇ. Under the Biologic Price Competition and Innovation Act (BPCIA) of 2009, which governs U.S. biosimilar development, an interchangeable biosimilar may be substituted in place of its reference product (in this case, Sanofi’s insulin glargine LantusⓇ) at the pharmacy without the […]

Australia Begins Forced Switching of Metastatic Cancer Patients

July 12, 2021

Bowel Cancer Australia has issued a Patient Alert for Australia’s metastatic cancer patients: beginning on June 1st, 2021, the popular drug Avastin will be withdrawn from Australia’s Pharmaceutical Benefit Scheme (PBS) meaning it will no longer be available to metastatic bowel cancer patients as a subsidized treatment. Avastin is designed to block a protein called vascular endothelial growth […]

AMA Passes ACR-led Resolution Opposing Paying Patients to Switch Treatments

July 12, 2021

On June 15th, the American Medical Association (AMA) passed a resolution opposing the practice of insurers providing financial incentives for patients to switch to a payer-preferred treatment. The resolution was drafted by the American Colloge of Rheumatology (ACR) and passed during the AMA’s June 2021 Special Meeting. The ACR drafted the resolution after learning Cigna was notifying patients […]

AMA Passes ACR-led Resolution Opposing Paying Patients to Switch Treatments

July 12, 2021

On June 15th, the American Medical Association (AMA) passed a resolution opposing the practice of insurers providing financial incentives for patients to switch to a payer-preferred treatment. The resolution was drafted by the American Colloge of Rheumatology (ACR) and passed during the AMA’s June 2021 Special Meeting. The ACR drafted the resolution after learning Cigna was notifying patients […]

ASBM Presents on Patient & Physician Perspectives at 15th Biosimilars Congregation

July 12, 2021

On June 24th, ASBM Executive Director Michael Reilly presented at the 15th Biosimilars Congregation. The event was organized to provide insight into the current state of play in the EU with respect to biosimilars and stimulate debate, in a multi-stakeholder setting, on the vital role of biosimilar medicines in the sustainability of healthcare systems. It also highlighted […]